Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications

Biochemical and Biophysical Research Communications

Volumn 438, Issue 2, 2013, Pages 324-328

  Xu, Baiying ^a   Di, Jianzhong ^a   Wang, Zhigang ^a   Han, Xiaodong ^a   Li, Zonghai ^a   Luo, Xiaoying ^a   Zheng, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

DNA methylation; HCC; Methylight; Prognostic biomarker; RASSF1A

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; DNA METHYLATION; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

DNA METHYLATION; HCC; METHYLIGHT; PROGNOSTIC BIOMARKER; RASSF1A;

AGE FACTORS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84882612657     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.07.070     Document Type: Article

References (20)

1. He Y., Cui Y., Wang W., Gu J., Guo S., Ma K., Luo X. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia 2011, 13(9):841-853.
2. Liu W.R., Shi Y.H., Peng Y.F., Fan J. Epigenetics of hepatocellular carcinoma: a new horizon. Chin. Med. J. 2012, 125(13):2349-2360.
3. Weisenberger D.J., Campan M., Long T.I., Kim M., Woods C., Fiala E., Ehrlich M., Laird P.W. Analysis of repetitive element DNA methylation by methylight. Nucleic Acids Res. 2005, 33(21):6823-6836.
4. Ogino S., Kawasaki T., Brahmandam M., Cantor M., Kirkner G.J., Spiegelman D., Makrigiorgos G.M., Weisenberger D.J., Laird P.W., Loda M., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J. Mol. Diagn. 2006, 8(2):209-217.
5. Um T.H., Kim H., Oh B.K., Kim M.S., Kim K.S., Jung G., Park Y.N. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J. Hepatol. 2011, 54(5):939-947.
6. Lou C., Du Z., Yang B., Gao Y., Wang Y., Fang S. Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci. 2009, 100(6):996-1004.
7. Nishida N., Kudo M., Nagasaka T., Ikai I., Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012, 56(3):994-1003.
8. Hernandez-Vargas H., Lambert M.P., Le Calvez-Kelm F., Gouysse G., McKay-Chopin S., Tavtigian S.V., Scoazec J.Y., Herceg Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010, 5(3):e9749.
9. Su H., Zhao J., Xiong Y., Xu T., Zhou F., Yuan Y., Zhang Y., Zhuang S.M. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat. Res. 2008, 641(1-2):27-35.
10. Harder J., Opitz O.G., Brabender J., Olschewski M., Blum H.E., Nomoto S., Usadel H. Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int. J. Cancer 2008, 122(12):2800-2804.
11. Gao W., Kondo Y., Shen L., Shimizu Y., Sano T., Yamao K., Natsume A., Goto Y., Ito M., Murakami H., et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008, 29(10):1901-1910.
12. Friedrich M.G., Chandrasoma S., Siegmund K.D., Weisenberger D.J., Cheng J.C., Toma M.I., Huland H., Jones P.A., Liang G. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer 2005, 41(17):2769-2778.
13. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., Danenberg P.V., Laird P.W. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28(8):E32.
14. Yeo W., Wong N., Wong W.L., Lai P.B., Zhong S., Johnson P.J. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005, 25(2):266-272.
15. Lee H.S., Kim B.H., Cho N.Y., Yoo E.J., Choi M., Shin S.H., Jang J.J., Suh K.S., Kim Y.S., Kang G.H. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15(3):812-820.
16. Di Gioia S., Bianchi P., Destro A., Grizzi F., Malesci A., Laghi L., Levrero M., Morabito A., Roncalli M. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC cancer 2006, 6:89.
17. Feng Q., Stern J.E., Hawes S.E., Lu H., Jiang M., Kiviat N.B. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp. Mol. Pathol. 2010, 88(2):287-292.
18. Zhong S., Yeo W., Tang M.W., Wong N., Lai P.B., Johnson P.J. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin. Cancer Res. 2003, 9(9):3376-3382.
19. Hu L., Chen G., Yu H., Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hep. Intl. 2010, 4(1):423-432.
20. Saelee P., Wongkham S., Chariyalertsak S., Petmitr S., Chuensumran U. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2010, 11(6):1677-1681.